2 Stock in focus after its shareholder lock-in ends; Unlocks ₹230 Cr worth shares

Synopsis: Certain investors in Orkla India Ltd and Amanta Healthcare Ltd are now eligible to sell their shares following the completion of the lock-in period. 

A lock-in period is a fixed duration during which certain investors, such as promoters or anchor investors, are restricted from selling their shares after an IPO or allotment. It is designed to ensure market stability by preventing large-scale selling immediately after listing and to demonstrate the investors’ long-term commitment to the company.

Once this period ends, the shares become eligible for trading in the open market. The lock-in period for anchor investors of Orkla India Ltd and Amanta Healthcare has ended, allowing them to sell their shares in the open market.

Orkla India

Orkla​‍​‌‍​‍‌​‍​‌‍​‍‌ India is the parent company of well-known food brands such as MTR, Eastern, and Rasoi Magic. Through their versatile products like spices, masalas, breakfast mixes, ready-to-eat sweets, and quick meals, they simplify the daily cooking of households. The company, located in Bangalore, also exports these consumables to Indian families living in 42 countries. Orkla India is a subsidiary of Orkla ASA, a major Norwegian company that has multiple businesses ​‍​‌‍​‍‌​‍​‌‍​‍‌worldwide.

With a market capitalisation of Rs 8,329 crore, the shares of Orkla India Ltd reached a day’s low of Rs 606.05 per share, down 2.4 percent from its previous day’s closing price of Rs 620.90 per share. Post listing on the stock exchange, the stock has corrected over 16 percent.

Approximately​‍​‌‍​‍‌​‍​‌‍​‍‌ 34 lakh shares of Orkla India, which is about 2 per cent of the company’s total equity, will be free of trading restrictions as their one-month lock-in period comes to an end. At the existing market rates, the shares that are unlocked on Wednesday are worth close to Rs 211 ​‍​‌‍​‍‌​‍​‌‍​‍‌crore.

Amanta Healthcare

Amanta​‍​‌‍​‍‌​‍​‌‍​‍‌ Healthcare is one of the expanding pharma companies, which is widely recognised for its commitment to innovation. Initially, it was established in 1998 as a manufacturer of IV fluids; however, it has increased its reach into irrigation solutions, eye and respiratory care, and small-volume injectables. At present, it acts as a reliable partner in contract manufacturing to leading pharma companies by providing them with a high level of proficiency in the production of sterile dosage ​‍​‌‍​‍‌​‍​‌‍​‍‌forms.

With a market capitalisation of Rs 411 crore, the shares of Amanta Healthcare Ltd reached a day’s low of Rs 102.60 per share, down 4 percent from its previous day’s closing price of Rs 106.85 per share. Post listing on the stock exchange, the stock has corrected by over 25 percent.

Approximately​‍​‌‍​‍‌​‍​‌‍​‍‌ 15 lakh shares of Amanta​‍​‌‍​‍‌​‍​‌‍​‍‌ Healthcare, which is about 4 per cent of the company’s total equity, are free of trading restrictions as their three-month lock-in period comes to an end. At the existing market rates, the shares that will be unlocked on Wednesday are worth close to Rs 16 ​‍​‌‍​‍‌​‍​‌‍​‍‌crore.

Written by Satyajeet Mukherjee

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 2 Stock in focus after its shareholder lock-in ends; Unlocks ₹230 Cr worth shares appeared first on Trade Brains.